KITE’S YESCARTA® CAR T-CELL THERAPY DEMONSTRATES A STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL FOR INITIAL TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA.

SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of care (SOC) in a curative setting for nearly 30 years, for initial treatment of adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy. Historical SOC is a multi-step process involving platinum-based salvage combination...